NCT06579755View on ClinicalTrials.gov

A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

800

Participants

Timeline

Start Date

April 1, 2026

Primary Completion Date

April 14, 2027

Study Completion Date

April 14, 2027

Conditions

Dengue Fever

Interventions

BIOLOGICAL

TDV

TDV SC injection.

OTHER

Placebo

Placebo SC injection.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY